

Index

- 7E11 antibody 191
- ¹¹C-acetate tracer 37
- ¹⁸F-acetate tracer 190–1
- adenocarcinoma location *see* zones of the prostate gland
- advanced prostate cancer
 - androgen-deprivation therapy 93, 95–97
 - bone metastases 179–81,
 - chemotherapy 97–98
 - clinical states model 93–95,
 - combination therapies 63–4
 - nuclear bone scan for metastases 179–81,
 - palliative therapy 98
 - targeted therapy (androgen receptor signaling axis) 98
 - therapeutic objectives 93–5,
 - use of imaging 35–7
- age-related benign prostatic hyperplasia *see* BPH (benign prostatic hyperplasia)
- American Joint Commission on Cancer (AJCC), staging of tumors 7, 9, 10
- anaplastic variant of prostate cancer 126
- anatomy and histology of the normal prostate gland 2–4,
- androgen deprivation therapy 9, 93, 95–7
 - alternative hormonal interventions 97
 - continuous versus intermittent hormone therapy 96–7
 - estrogens 95–6
 - gonadotropin-releasing hormone analogs 95–6
 - ketoconazole therapy 97
 - non-steroidal anti-androgens 95–6
 - orchiectomy 95–6
 - potential side-effects 95–6,
 - prediction of risk of metastasis 94
 - primary androgen depletion 95–6
 - PSA kinetics 94
 - timing of hormonal therapy 96
- androgen-independent tumors 93, 97
- androgen receptor blocking therapies 38
- androgen receptor imaging agents 188, 189
- androgen receptor signaling axis 98
- androgen suppression, combined with radiation therapy 79, 80
- angiogenesis in cancer, detection 123–4
- anterior fibromuscular stroma (AFMS) 2, 3, 102–3
- antibodies
 - 7E11 191
 - ¹¹¹In-capromab pendetide (PMSA antibody) 37
- BASING (band selective inversion with gradient dephasing) 141–2, 161–2
- benign prostatic hyperplasia *see* BPH (benign prostatic hyperplasia)
- bicalutamide 95–96
- biopsy 29–30
 - MR imaging-guided prostate biopsy 146–7
 - MR imaging of post-biopsy haemorrhage 140–1
 - see also* TRUS-guided biopsy
- bone metastases in advanced prostate cancer 179–81, follow-up of systemic therapy 38
- imaging of recurrent prostate cancer 202–4,
- palliative therapy 98
- post-treatment detection 35–7
- pretreatment detection 35
- bone scan
 - follow-up of systemic therapy 38
 - recommendations 35
 - see also* nuclear medicine imaging in metastatic cancer
- bone scan index (BSI) 38, 181, 182
- bony ablation treatment 36
- bowel toxicity following radiation therapy 71, 77
- BPH (benign prostatic hyperplasia) 2, 3, 103, 106, 107–11
- brachytherapy 59, 72–9
 - biologic effective dose (BED) concept 75
 - combined modality approaches 77–9,
 - definition 72
 - dose 74–5
 - external beam radiation combined with 77–9,
 - modern permanent (LDR) brachytherapy 72–3

224 Index

- brachytherapy (cont.)
 - morbidity after treatment 76–7
 - salvage brachytherapy 82–3
 - temporary (HDR) brachytherapy 75–6
- branched duct gland histology of the prostate gland 3
- ¹¹C-acetate tracer 37
- ¹¹C-choline tracer 37
- ¹¹C-methionine tracer 37, 60, 188–90,
 - calculi 3
- capromab imaging 37
 - ¹¹¹In-capromab pendetide (PMSA antibody) 37
- capsule (prostatic) 3
 - invasion by prostatic cancer 7,
 - TRUS imaging 103
- carcinoma location *see* zones of the prostate gland
- castrate-resistant rising PSA and clinical metastases
 - chemotherapy 97–8
 - palliative therapy 98
 - targeted therapy (androgen receptor signaling axis) 98
- CBCT (cone-beam computed tomography) imaging 68–9
- central zone (prostate gland) 2, 3, 102–3
 - neoplastic potential and prognosis 8
- chemotherapy 97–8
 - assessment of response 38
 - use of imaging in follow-up 38
- choline-containing compounds in tumors 158–60,
 - ¹¹C-choline tracer 37
 - ¹⁸F-choline tracer 190–1
- chronic prostatitis 2–3
- citrate levels in tumors 158–9, 160
- clinical assessment, added value of MR imaging 150–1
- clinical sequelae of prostate cancer, variability 15–16,
- clinical states model of prostate cancer 93–5, 177, 178
- color doppler ultrasound 106, 107–11,
- combined therapies 63–4
 - combined radiation therapy modalities 77–9,
 - external beam radiation with brachytherapy 77–9,
 - radiation therapy with androgen suppression 79, 80
 - radiation therapy with hormone therapy 79, 80
- computed tomography *see* CT (computed tomography) imaging
- contrast-enhanced ultrasound 108, 109, 111–14
- corpora amylacea 3, 103
- creatine/phosphocreatine levels in tumors 158–9, 160
- cryotherapy 196, 198
- CT (computed tomography) imaging 29
 - combination with FDG-PET 36–7,
 - DCE (dynamic contrast-enhanced) CT 123–4
 - detection and staging of primary prostate cancer 121–4,
 - detection of metastases 36–7,
 - evaluation for metastatic recurrent prostate cancer 202–4,
 - follow-up of systemic therapy 38
 - pretreatment detection of lymph node metastases 35
 - radiation therapy planning 59–60
 - staging of systemic disease 124–9,
 - treatment follow-up 131–6,
 - treatment planning 129–31
 - uses and limitations in prostate cancer 120–1
- curative therapy following watchful waiting 21, 22
- DCE (dynamic contrast-enhanced) CT 123–4
- DCE (dynamic contrast-enhanced) MRI 123–4,
 - 141, 172
- delayed curative therapy following watchful waiting 21, 22
- Denonvilliers' fascia 2
- diagnosis of prostate cancer
 - biopsy 29–30
 - digital rectal examination (DRE) 29–30
 - gross identification of tumors 5
 - lifetime risk 15
 - morphologic diagnosis of prostate adenocarcinoma 5
 - TRUS-guided biopsy 29–30
 - use of imaging 29–30
- diffusion-weighted imaging (DWI) 171
- diffusion-weighted MR imaging 141
- digital rectal examination *see* DRE (digital rectal examination)
- 5 α -dihydrotestosterone 1
- docetaxel 97–8
- double spin-echo technique *see* PRESS technique
- DRE (digital rectal examination) 29–30
 - detection of local recurrence after radiation therapy 204
 - detection of tumor recurrence 33
 - limitations for staging 45
- DRE-guided biopsy, detection of local recurrence after RP 210–13
- dynamic contrast-enhanced CT (DCE-CT) 123–4
- dynamic contrast-enhanced MRI (DCE-MRI) 123–4,
 - 141, 172
- early detection programs 4–5 *see also* PSA screening
- ejaculatory duct complex 3, 103
- elastography 114–16,
- embryology and development of the prostate gland 1
- eMRI (endorectal MRI), use in preoperative assessment 46–7,
- endocrine therapy, effects on primary prostate adenocarcinoma 8–9
- epidemiology of prostate cancer 4–5
- erectile dysfunction following radiation therapy 71, 77
- erectile function
 - nerve-sparing surgery 4
 - recovery following surgery 48, 49–50, 53
- estrogen therapy 9, 95–6, 97
- expectant management *see* watchful waiting approach
- external beam radiation therapy 64
 - combination with brachytherapy 77–9,
- extracapsular extension
 - and prognosis 6, 7,
 - surgical technique 48–9, 50, 51

- ¹⁸F acetate radiotracer 190–1
- ¹⁸F choline radiotracer 190–1
- ¹⁸F-FACBC tracer 190, 191
- ¹⁸F fluorohydrotestosterone (FDHT) tracer 38, 60
- FDG (¹⁸F 2-fluoro-2-deoxy-D-glucose) imaging 36, 60, 183–6,
 - FDG-PET imaging 183–6,
 - assessment of castrate-resistant prostate cancer 184–6,
 - follow-up of systemic therapy 38
- FDG-PET/CT
 - follow-up of systemic therapy 38
 - use for detection of metastases 36–7,
- FDHT (¹⁸F-fluorodihydrotestosterone) PET 38
- flutamide 95–6
- functional imaging 177 *see also* nuclear medicine
 - imaging in metastatic cancer
- gene therapy 9
- Gleason system of histological grading 5–6,
 - undergrading of prostate cancer 44–5
- gonadotropin-releasing hormone analogs 95–6
- grading of prostate cancer
 - Gleason system 5–6,
 - undergrading 44–5,
- gray-scale ultrasound 104–7
- gross identification of tumors 5
- helical tomotherapy 69
- HIFU (high-intensity focused ultrasound) therapy 196, 198
- histological grading of prostate cancer 5–8,
- histology and anatomy of the normal prostate gland 2–4,
- histone deacetylase inhibitors 98
- histopathology of prostate adenocarcinoma 103–4
- histopathology of the prostate gland 103–4
- hormone therapy 22–3, 59
 - androgen deprivation therapy 93, 95–7
 - combined with radiation therapy 79, 80
 - effects on primary prostate adenocarcinoma 8–9
 - secondary hormonal therapies 93
 - use of imaging in follow-up 38
- Hsp90 chaperone inhibitors 98
- HSV-tk ganciclovir gene therapy 9
- hypofractionated radiotherapy 70
- imaging
 - follow-up of systemic therapy 38
 - image-guided radiation therapy 64, 68–9
 - prediction of intraoperative blood loss 32
 - prediction of urinary continence recovery time 32–3
 - role in preoperative assessment 45–7,
 - roles in prostate cancer management 29
 - types of imaging 29
 - use in diagnosis 29–30
 - use in radiation treatment planning 58–60
 - use in surgical treatment planning 32–3
 - see also* nuclear medicine imaging in metastatic cancer *and specific types of imaging*
- imaging in detection of advanced disease 35–7
 - bone metastases 35
 - lymph node metastases 33, 35,
 - monoclonal antibody imaging 37
 - post-treatment detection of metastases 35–7
 - pretreatment detection of metastases 35
 - technetium bone scan 35
 - tumor recurrence 33–4
- imaging in treatment selection 30–2
 - assessing clinically significant cancer 31–2
 - combination MRI/MRSI in nomogram models 31
 - identifying potentially insignificant cancer 30–1
 - local staging of prostate cancer 31–2
 - MRI/MRSI use in active surveillance 31
 - use in nomograms to predict indolent cancers 30–1
- imaging of recurrent prostate cancer 195–216
 - detection of bone metastases 202–4,
 - detection of lymphadenopathy 202
 - evaluation for metastatic recurrent prostate cancer 202–4,
 - guidelines for interpretation of prostate studies 196, 199, 200, 201
 - imaging of local recurrence after radiation therapy 204–10
 - imaging of local recurrence after RP 210–16
 - nuclear medicine imaging 215–16
 - patient selection after radiation therapy 199–200,
 - patient selection after RP 200–1,
 - principles of prostate cancer management 195–9, 200, 201
 - TRUS-guided systematic biopsy 195, 196
- IMRT (intensity modulated radiation therapy) 64
- ¹¹¹In-capromab pentetide (PMSA antibody) 37
- incidence of prostate cancer 4–5, 15
- indolent (insignificant) prostate cancer 15–16,
 - definition 31
 - predictive models 19–21
 - use of imaging to identify 30–1
 - use of nomograms to identify 30–1
- insignificant cancer *see* indolent prostate cancer
- International Union Against Cancer (UICC), staging of tumors 7,
- intraoperative blood loss 32, 52–3
- J591 antibody 37, 191–2,
- ketoconazole therapy 97
- lobes of the prostate gland 2
- lower urinary tract symptoms following radiation therapy 70–1, 76
- lymph node metastases 3–4
 - post-treatment detection 35–7
 - pretreatment detection 35,
 - use of imaging to identify 33
- lymph node staging, role of MR imaging 150
- lymph node status, and prognosis 6, 7
- lymphadenopathy, imaging of recurrent prostate cancer 202

226 Index

- magnetic resonance imaging (MRI) 29
- McNeal's work on zones of the prostate gland 2–3, 8
- megavoltage CBCT imaging 68–9
- megavoltage CT imaging 69
- membranous urethral length, preservation during surgery 50–1, 52
- metastatic prostate cancer 3–4
 - areas affected 9
 - post-treatment detection 35–7
 - pretreatment detection 35
 - recurrent disease after radical prostatectomy 22–3
 - staging and metastatic spread 9, 10
 - see also* advanced prostate cancer, nuclear medicine imaging in metastatic cancer
- ¹¹C methionine tracer 37, 60, 188–90,
- microvessel density and cancer detection 123–4
- mitoxantrone 97–8
- molecular imaging 177 *see also* nuclear medicine imaging in metastatic cancer
- monoclonal antibody imaging 37
- morphologic diagnosis of prostate adenocarcinoma 5
- mortality rate for prostate cancer 4–5, 15,
- MR (magnetic resonance) imaging *see* MRI (magnetic resonance imaging)
- MR spectroscopic imaging *see* MRSI (MR spectroscopic imaging)
- MRI (magnetic resonance imaging)
 - added value to clinical assessment 150–1
 - appearance of normal prostate 142–4,
 - appearance of prostate cancer 144–6,
 - detection of local recurrence after radiation therapy 204–10, 211
 - detection of local recurrence after RP 213–15, 216, 217, 218
 - detection of tumor recurrence 33–4,
 - evolving role in prostate cancer 140
 - follow-up of systemic therapy 38
 - identification of lymph node metastases 33
 - local staging of prostate cancer 31–2
 - lymph node staging 150
 - MR imaging-guided prostate biopsy 146–7
 - prediction of urinary continence recovery time 32–3
 - pretreatment detection of lymph node metastases 35,
 - role in assessment of recurrent disease 152–4,
 - role in treatment planning 151–2
 - tumor detection and localization 147–8
 - tumor staging 148–50,
 - use for detection of bone metastases 36, 37
 - use in assessment of prostate cancer 146–51
 - use in diagnosis 29–30
 - use in radiation therapy planning 59–60
 - use in surgical treatment planning 32–3
 - use of USPIO particles 35
- MRI techniques 140–2
 - diffusion-weighted MR imaging 141
 - dynamic contrast-enhanced MR imaging 141
 - imaging parameters 140–1
 - MR spectroscopy 141–2
 - post-biopsy hemorrhage 140–1
 - three-dimensional proton MR spectroscopic mapping 141–2
 - see also* DCE (dynamic contrast-enhanced) MRI, eMRI
- MRI/MRSI combination
 - use in active surveillance 31
 - use in nomogram models 31
 - use to assess clinically significant cancer 31–2
- MRSI (MR spectroscopic imaging) 141–2
 - after definitive therapy 169–71
 - assessment of metabolites in the prostate gland 158–60,
 - band-selective inversion and dephasing (BASING) 161–2
 - biological basis of prostate spectral patterns 158–60,
 - CART-based decision-making tree for voxel analysis 164–5, 166,
 - choline-containing compounds in tumors 158–60,
 - citrate levels in tumors 158–9, 160
 - combination with MRI 31
 - creatine/phosphocreatine levels in tumors 158–9, 160
 - criteria for MRSI data interpretation 163–5, 166,
 - detection of tumor recurrence 33–4
 - diffusion-weighted imaging (DWI) 171
 - double spin-echo technique 160
 - dynamic contrast-enhanced MRI (DCE-MRI) 172
 - need for good shimming 161
 - point-resolved spectroscopy (PRESS) technique 160, 161
 - polyamine levels in tumors 158–9, 160
 - PROSE software 164–5
 - stimulated echo acquisition (STEAM) technique 160
 - technical developments in prostate MR spectroscopy 160–3
 - untreated prostate gland 165–9,
 - use in preoperative assessment 47
 - use in radiation therapy planning 60
 - voxel characterization 163–5, 166,
 - water and fat suppression issues 161–2
- National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology for Prostate Cancer 196, 199, 200, 201
- natural history of prostate cancer
 - and accurate risk-stratification of patients 15–16
 - delayed curative therapy following watchful waiting 21, 22
 - effects of early intervention (ongoing trials) 23–5
 - impact of surgical intervention 23, 24
 - impacts of PSA testing 19–21,
 - pre-PSA studies 16–18,
 - predictive models 19–21
 - recurrent disease 22–3
 - treated prostate cancer 22–3, 24
 - untreated prostate cancer (watchful waiting) pre-PSA 16–18,
 - watchful waiting approach (pre-PSA) 16–18,
 - watchful waiting approach (PSA era) 19–21,

- neoplastic potential of zones of the prostate 8
- neural anatomy of the prostate gland 4
- neurovascular bundle preservation during surgery 4, 48–50,
- nilutamide 95–6
- nodular hyperplasia 8
- nomograms
 - post-treatment risk of bone metastases 35–6
 - preoperative staging of prostate cancer 44, 45
 - to identify indolent (insignificant) cancer 30–1
- non-steroidal anti-androgens 95–6
- nuclear bone scan technique 178–9
- nuclear medicine imaging, detection of local recurrence after RP 215–16
- nuclear medicine imaging future applications 187–92
 - androgen receptor imaging agents 188, 189
 - potential of new tracers 188–91,
 - radiolabeled antibody imaging 191–2,
- nuclear medicine imaging in metastatic cancer 177–8
 - assessment of castrate-resistant prostate cancer 184–6,
 - bone metastases 179–81,
 - bone scan index (BSI) 181, 182
 - detection of disease in patients with PSA relapse after RP 186–7
 - FDG in castrate-resistant prostate cancer 184–6,
 - FDG-PET imaging 183–6,
 - measures of tumor metabolism in metastatic disease 183–4
 - monitoring progression or treatment response 181–3,
 - nuclear bone scan technique 178–9
 - quantitative tool (bone scan index, BSI) 181, 182
 - radiolabeled antibody imaging 187
 - time-course of bone metastasis development 181–3,
- observation only approach 16–18, *see also* watchful waiting approach
- orchiectomy 9, 95–96
- palliative therapy 98
- pelvic lymph node metastases 3–4
- pelvic MRI, detection of local recurrence after RP 213–15, 216, 217, 218
- perineural invasion and prognosis 6, 7–8,
- peripheral zone (prostate) 2–3, 102–3
 - neoplastic potential and prognosis 8
- periprostic lymph node metastases 3–4
- periseminal vesicle lymph node metastases 3–4
- periurethral zone (prostate) 8, 102–3
- PET (positron emission tomography) 29, 177
 - ¹¹C-acetate tracer 37
 - ¹¹C-choline tracer 37
 - ¹¹C-methionine tracer 37, 60, 188–90,
 - ¹⁸F-acetate tracer 190–1
 - ¹⁸F-choline tracer 190–1
 - ¹⁸F-FACBC tracer 190, 191
 - ¹⁸F-fluorohydrotestosterone (FDHT) tracer 38, 60
 - FDG tracer 36, 60 *see also* FDG-PET/CT
 - FDHT (¹⁸F-fluorodihydrotestosterone) PET 38
 - potentially useful radiotracers for metastases 188–91,
 - use in radiation therapy planning 60
 - see also* FDG-PET
- PET/CT 29 *see also* FDG-PET/CT
- polyamine levels in tumors 158–9, 160
- positron-emission tomography *see* PET (positron-emission tomography)
- posterior part of the prostate *see* peripheral zone
- postinflammatory atrophy 2–3
- postoperative nomograms, prognostic information 6, 7
- postoperative predictors of metastatic development and survival 22–3
- power doppler ultrasound 106, 107–11,
- predictive models for tumor indolence 19–21
- prednisone 97–98
- presentation of prostate cancer 4–5
- PRESS (point-resolved spectroscopy) 141–2, 160, 161
- prognostic information
 - capsular invasion 7,
 - extracapsular extension 6, 7,
 - Gleason grading system 5–6,
 - lymph node status 6, 7
 - perineural invasion 6, 7–8,
 - postoperative nomograms 6, 7
 - quantification of intratumoral reactive stroma 8
 - significance of lymph node metastases 3–4
 - significance of seminal vesicle involvement (SVI) 3, 4, 6, 7
 - staging of tumors 7,
 - surgical margin status 6, 7
 - zonal origin of prostate cancer 8
- prognostic risk stratification 60–2,
- ProstaScint® 37, 191
- prostate gland
 - adult weight 1
 - anterior fibromuscular stroma 2, 3, 102–3
 - branched duct gland histology 3
 - capsule 3, 7, 103
 - central zone 2, 3, 8, 102–3
 - embryology and development 1
 - lobes concept 2
 - location 2
 - neural anatomy 4
 - normal anatomy and histology 2–4,
 - peripheral zone 2–3, 102–3
 - periurethral zone 8, 102–3
 - transition zone 2, 3, 8, 102–3
 - zonal anatomy 2–3, 8, 102–3
- prostate MRI, detection of local recurrence after radiation therapy 204–10, 211
- PSA (prostate-specific antigen) levels
 - definition of treatment failure 62–3
 - limitations to interpretation 44
 - relapse criteria 198
- PSA (prostate-specific antigen) screening 4–5
 - detection of tumor recurrence 33
 - impacts on detection, staging and awareness 19–21,
 - recurrent disease after radical prostatectomy 22–3

228 Index

- PSMA (prostate-specific membrane antigen),
 ProstaScint® binding 191
- PSMA (prostate-specific membrane antigen) antibody,
¹¹¹In-capromab pendetide 37
- puberty, development of the prostate gland 1
- radiation therapy 22–3
 acute and late toxicity after external beam
 radiotherapy 70–1
 adjuvant radiation therapy 81
 bowel toxicity 71, 77
 brachytherapy 72–9
 choice of local therapy 63–4
 combination therapies 63–4
 combined modality approaches 77–9,
 combined with androgen suppression 79, 80
 combined with hormone therapy 79, 80
 cone-beam computed tomography (CBCT) imaging
 68–9
 definition of treatment failure 62–3
 definitions of biochemical outcome 62–3
 detection of tumor recurrence 33–4,
 dose escalation and biochemical outcome 65–8,
 dose-volume histograms 64
 effects on primary prostate adenocarcinoma 8–9
 erectile dysfunction 71, 77
 external beam radiation therapy 64
 helical tomotherapy 69
 history of role in prostate cancer management 58
 hypofractionated radiotherapy 70
 image-guided radiation therapy 68–9
 image-guided technologies 64
 imaging of local recurrence 204–10
 intensity modulated radiation therapy (IMRT) 64
 inverse planning of treatment 64
 lower urinary tract symptoms 70–1, 76
 megavoltage CBCT imaging 68–9
 megavoltage CT imaging 69
 patient selection and prognostic risk 60–2,
 prognostic risk stratification 60–2,
 salvage radiation therapy 81–3,
 use of imaging for patient selection 58–60
 use of imaging for pretreatment assessment 58–60
 use of imaging for treatment planning 58–60
 use of imaging in follow-up 38
 use of MRI before and after treatment 33–4
 use of MRI to assess recurrent tumors 152–4,
 use of MRI/MRSI to detect recurrent disease 169–71,
- radical prostatectomy (RP) 1
 definition of treatment failure 62
 detection of tumor recurrence 33, 34
 effectiveness as a treatment option 43
 effects of early intervention 23, 24
 effects of early intervention (ongoing trials) 23–5
 FDG-PET detection of disease in patients with PSA
 relapse 186–7
 imaging of local recurrence 152, 153, 170–1, 210–16
 option to delay treatment 21, 22
 outcomes 53
 prediction of urinary continence recovery time 32–3
 treatment of recurrent disease 22–3
 use of imaging in surgical planning 32–3
- radical prostatectomy preoperative assessment 44–7
 limitations in clinical staging 44–5
 role of imaging 45–7,
 undergrading 44–5,
 understaging 45,
- radical prostatectomy surgical technique
 achieving a negative surgical margin 48–9, 50, 51
 erectile function recovery 48, 49–50
 extracapsular extension 48–9, 50, 51
 intraoperative blood loss 52–3
 neurovascular bundle preservation 48–50,
 optimal treatment strategy 47–8
 preservation of membranous urethral length
 50–1, 52
 tailoring to the individual patient 47–53
 urinary incontinence and apical dissection 50–1, 52
- radioactive isotopes, palliative therapy 98
- radiolabeled antibody imaging 187, 191–2,
- radionuclide bone scanning 29
- reactive stroma, classification 8
- recurrent prostate cancer
 monitoring after treatment 33–4
 monitoring with MRI and MRSI imaging 33–4,
 169–71
 monitoring with PSA testing and DRE 33
 predictors of metastatic development and survival
 22–3
 role of MR imaging in assessment 152–4,
see also imaging of recurrent prostate cancer
- 5α-reductase 1
- risk of developing prostate cancer 15
- risk-stratification of patients, importance of 15–16
- salvage brachytherapy 82–3
- salvage therapies 98, 196, 198–9
- screening for prostate cancer *see* PSA
 (prostate-specific antigen) screening
- secondary hormonal therapies 93
- seminal vesicles 3
 involvement by prostate cancer 3, 4
 prognosis of seminal vesicle involvement (SVI) 6, 7
 TRUS imaging 103
- small-cell variant of prostate cancer 126
- SPECT (single photon emission computerized
 tomography) 177
- stage at presentation with prostate cancer 4–5
- staging of tumors
 interpretation of PSA levels 44
 limitations in clinical staging 44–5
 limitations to DRE technique 45
 nomograms 44, 45
 prognostic information 7,
 role of MR imaging 148–50,
 understaging of prostate cancer 45,
 use of imaging techniques 31–2
- staging systems for prostatic adenocarcinoma 9, 10

- AJCC system 9, 10
- metastatic spread 9, 10
- TNM (Tumor – Lymph node – Metastasis) system 9, 10
- STEAM (stimulated echo acquisition) technique 160
- stromogenic cancer 8
- surgical margin status
 - achieving a negative surgical margin 48–9, 50, 51
 - and prognosis 6, 7
- surgical pathology of the prostate gland 4–8
 - clinical aspects of epidemiology 4–5
 - early detection programs 4–5
 - Gleason system of histological grading 5–6,
 - gross identification of tumors 5
 - histology of prostate cancer 5–8,
 - morphologic diagnosis of prostate adenocarcinoma 5
- screening with serum prostate specific antigen (PSA) 4–5
- stage at presentation 4–5
- surgical technique
 - achieving a negative surgical margin 48–9, 50, 51
 - erectile function recovery 48, 49–50
 - extracapsular extension 48–9, 50, 51
 - intraoperative blood loss 52–3
 - neurovascular bundle preservation 48–50,
 - optimal treatment strategy 47–8
 - preservation of membranous urethral length 50–1, 52
 - tailoring to the individual patient 47–53
 - urinary incontinence and apical dissection 50–1, 52
- surgical treatment of prostate cancer
 - definition of treatment failure 62
 - effects of early intervention 23, 24
 - effects of early intervention (ongoing trials) 23–5
 - impact on the natural history of prostate cancer 23, 24
 - MR imaging in assessment of recurrent tumor 152, 153
 - nerve-sparing 4
 - prediction of urinary continence recovery time 32–3
 - selection of optimal treatment approach 43
 - see also* radical prostatectomy
- surgical treatment planning
 - prediction of intraoperative blood loss 32
 - use of imaging 32–3
- surgical treatment preoperative assessment 44–7
 - limitations in clinical staging 44–5
 - role of imaging 45–7,
 - undergrading 44–5,
 - understaging 45,
- systemic therapy, use of imaging in follow-up 38 *see also* androgen deprivation therapy
- targeted therapy (androgen receptor signaling axis) 98
- technetium (^{99m}Tc) bone scan 35, 178–9
- testosterone
 - 5 α -dihydrotestosterone 1
 - fetal 1
- therapeutic options for clinically localized prostate cancer 63–4
- three-dimensional proton MR spectroscopic mapping 141–2
- TNM (Tumor – Lymph node – Metastasis) staging system 9, 10
 - limitations of DRE technique 45
- transition zone (prostate) 2, 3, 102–3
 - neoplastic potential and prognosis 8
- transrectal ultrasound *see* TRUS (transrectal ultrasound) imaging
- treated prostate cancer, natural history 22–3, 24
- treatment of prostate cancer
 - clinical management challenges 15–16,
 - complications of 15
 - delayed curative therapy following watchful waiting 21, 22
 - effects on primary prostate adenocarcinoma 8–9
 - impacts of PSA testing 19–21,
 - indolent tumors 15–16,
 - need for accurate risk-stratification of patients 15–16
 - option to delay radical prostatectomy 21, 22
 - predictive models for tumor indolence 19–21
 - recurrent disease 22–3
 - selection of optimal treatment approach 43
 - treatment-resistant metastatic disease 15
 - variability of clinical sequelae 15–16,
 - watchful waiting approach (pre-PSA) 16–18,
 - watchful waiting approach (PSA era) 19–21,
 - see also* hormone therapy, radiation therapy, radical prostatectomy, surgical treatment
- treatment planning, role of MR imaging 151–2
- TRUS (transrectal ultrasound) imaging 29
 - benign prostatic hyperplasia (BPH) 103, 106, 107–11
 - color doppler ultrasound 106, 107–11,
 - conditions which may mimic prostate cancer 106
 - contrast-enhanced ultrasound 108, 109, 111–14
 - conventional gray-scale ultrasound 104–7
 - detection of local recurrence after radiation therapy 204
 - elastography 114–16,
 - histopathology of the prostate gland 103–4
 - patient preparation and positioning 104–5
 - power doppler ultrasound 106, 107–11,
 - prostate adenocarcinoma histopathology 103–4
 - role in detection and management of prostate cancer 102
 - sonographic anatomy 102–3
 - ultrasound imaging technique 105–7,
 - use in preoperative assessment 45–6
 - zonal architecture of the prostate gland 102–3
- TRUS-guided biopsy 29–30
 - detection of local recurrence after radiation therapy 204
 - detection of local recurrence after RP 210–13
- TRUS-guided systematic biopsy 195, 196
- tumor aggressiveness, Gleason grading 44–5,
- tumor detection and localization, role of MR imaging 147–8

230 Index

- tumor recurrence monitoring *see* recurrent prostate cancer
- tumor staging *see* staging of tumors
- ultrasound *see* TRUS (transrectal ultrasound) imaging
- urinary incontinence
 - and apical dissection 50–1, 52
 - following surgery 50–1, 52, 53
 - prediction of continence recovery time after surgery 32–3
- USPIO (ultrasmall superparamagnetic iron oxide)
 - particles, use with MRI 35
- utricle 3
- vas deferens 3, 103
- watchful waiting approach (pre-PSA) 16–18,
- watchful waiting approach (PSA era) 19–21,
 - comparison with early intervention (ongoing trials) 23–5
 - comparison with early radical prostatectomy 23, 24
 - delayed curative therapy 21, 22
 - effectiveness of delayed interventions 21, 22
 - post-prostatectomy recurrences 22–3
- zoledronic acid 98
- zones of the prostate gland 2–3,
 - location of prostate adenocarcinoma 8
 - neoplastic potential 8
 - TRUS imaging 102–3
- zonal origin of prostate cancer and prognosis 8